BEAM-101 is an ex vivo genetic therapy delivered as part of an autologous haematopoietic stem cell transplant (HSCT) after a ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology ...

Trials have been completed on a new weapon system that directs a number of high-powered beams onto a single target.

BMO Capital says the first-ever clinical data from Beam Therapeutics (BEAM)’ base editing platform in sickle cell disease, or SCD, ...

Beam Therapeutics gave an initial look at the first handful of patients who received its experimental gene-edited treatment ...

Living Off The Land & Ocean in Remote Australia (Sharks, Swimming Holes & Ancient Art) (Ep9) Watch unbelievable moments as ...

CAMAS, Wash., November 05, 2024--nLIGHT, Inc. (Nasdaq: LASR), a leading provider of high-power semiconductor and fiber lasers used in the industrial, microfabrication, aerospace, and defense markets, ...

The Chief Executive Officer (CEO) of the Housing and Construction Mayor Limited, My-ACE China, has urged journalists in ...